RAD.AX - Radiopharm Theranostics Limited

ASX - ASX Delayed price. Currency in AUD

Radiopharm Theranostics Limited

62 Lygon Street
Level 3
Carlton, VIC 3053
61 3 9824 5254

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDFounder & Exec. Chairman291.04kN/A1956
Mr. Riccardo CanevariMD, CEO & Director2.06MN/AN/A
Mr. Phillip HainsCFO & Company Sec.N/AN/AN/A
Prof. David MozleyChief Medical Officer & Scientific Advisory Board Chair860.77kN/AN/A
Mr. Vittorio Puppo M.D.Chief Operating OfficerN/AN/AN/A
Dr. Thomas H. Tulip Ph.D.Chief Technical OfficerN/AN/A1953
Dr. Scot L. Harper Ph.D.Sr. VP of Clinical OperationsN/AN/A1957
Mr. Bill ReganSr. VP of Regulatory StrategyN/AN/AN/A
Dr. Rama Abu ShmeisSr. VP of Chemistry, Manufacturing & ControlsN/AN/AN/A
Mr. Nathan Jong C.A.Company Sec.N/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Radiopharm Theranostics Limited develops radiopharmaceutical products for diagnostic and therapeutic uses. The company was incorporated in 2021 and is based in Carlton, Australia.

Corporate governance

Radiopharm Theranostics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.